Literature DB >> 24445621

Initiation of ECMO for ventilator-dependent respiratory failure in an infant with Pompe's.

Christina Riojas1, Walter Pipkin.   

Abstract

We present a 7-month-old male with Pompe's disease with respiratory failure requiring extracorporeal membrane oxygenation that received enzyme replacement therapy. There are no published cases of the use of extracorporeal membrane oxygenation in a patient with Pompe's disease, or the use of enzyme replacement therapy in the setting of acute respiratory failure.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24445621     DOI： 10.1007/s00383-014-3470-5

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN： 0179-0358            Impact factor:   1.827


  8 in total

1.  Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

Authors:  H Van den Hout; A J Reuser; A G Vulto; M C Loonen; A Cromme-Dijkhuis; A T Van der Ploeg
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

2.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

3.  Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation.

Authors:  Cyril Flamant; Fazia Hallalel; Paul Nolent; Jean-Yves Chevalier; Sylvain Renolleau
Journal:  Eur J Pediatr       Date:  2004-11-25       Impact factor: 3.183

4.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

Authors:  Priya Sunil Kishnani; Marc Nicolino; Thomas Voit; R Curtis Rogers; Anne Chun-Hui Tsai; John Waterson; Gail E Herman; Andreas Amalfitano; Beth L Thurberg; Susan Richards; Mark Davison; Deyanira Corzo; Y T Chen
Journal:  J Pediatr       Date:  2006-07       Impact factor: 4.406

5.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

Review 6.  Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO.

Authors:  Anne Greenough
Journal:  Paediatr Respir Rev       Date:  2009-06       Impact factor: 2.726

7.  Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

Authors:  Yoav H Messinger; Nancy J Mendelsohn; William Rhead; David Dimmock; Eli Hershkovitz; Michael Champion; Simon A Jones; Rebecca Olson; Amy White; Cara Wells; Deeksha Bali; Laura E Case; Sarah P Young; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2012-01       Impact factor: 8.822

8.  Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.

Authors:  A Amalfitano; A R Bengur; R P Morse; J M Majure; L E Case; D L Veerling; J Mackey; P Kishnani; W Smith; A McVie-Wylie; J A Sullivan; G E Hoganson; J A Phillips; G B Schaefer; J Charrow; R E Ware; E H Bossen; Y T Chen
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.